A new generation of orally active antithrombotics: Comparing strategies in the GPllb/Illa, thrombin and factor XA areas

Drugs of the Future

Volumn 25, Issue 4, 2000, Pages 369-383

  Adang, Anton E P ^a   Rewinkel, Jos B M ^b  

^a Research and Development   (Netherlands)

^b NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 AMIDINOPHENYL) 2 (1,2,3,4 TETRAHYDRO 2 METHYL 7 ISOQUINOLINYLSULFONAMIDO)PROPIONYL] 1,2,3,6 TETRAHYDRO 4 METHYLPICOLINIC ACID; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 DP 4147; 3 [1 [3 (4 PIPERIDINYL)PROPIONYL]NIPECOTOYLAMINO] 3 (3 PYRIDYL)PROPIONIC ACID; 3 [3 (AMINOIMINOMETHYL)PHENYL] N (2' AMINOSULFONYL 1,1' BIPHENYL 4 YL) 4,5 DIHYDRO 5 (1H TETRAZOL 1 YLMETHYL) 5 ISOXAZOLECARBOXAMIDE; 3 [[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETAMIDO] N [(3,5 DIMETHYL 4 ISOXAZOLYL)SULFONYL]ALANINE; 3 [[4 [[4 (AMINOIMINOMETHYL)PHENYL]AMINO] 1,4 DIOXOBUTYL]AMINO] 4 PENTYNOIC ACID; 3 [[[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETYL]AMINO] N (BUTOXYCARBONYL)ALANINE; 4 (4 AMIDINOBENZOYLGLYCYL) 3 METHOXYCARBONYLMETHYL 2 OXO 1 PIPERAZINEACETIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; L 734217; LAMIFIBAN; MELAGATRAN; MOL 144; N ACETYL 4 (AMINOIMINOMETHYL)PHENYLALANYL 2 CYCLOHEXYLGLYCYL 3 (1 METHYLPYRIDINIUM 3 YL) ALANYLLEUCYLPROLINAMIDE; ORBOFIBAN; ORG 39430; ROXIFIBAN; SC 57101; THROMBIN INHIBITOR; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XEMILOFIBAN; ZK 807191; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID METHANESULFONATE; [[[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETYL]AMINO] N [(3 METHYLPHENYL)SULFONYL]ALANINE;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

EID: 0034126830     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.04.858662     Document Type: Review

References (93)

1. Scharf, R.E., Harker, L.A. Thrombosis and atherosclerosis: Regulatory role of interactions among blood components and endothelium. Blut 1987, 55: 131-44.
2. Fuster, V., Stein, B., Ambrose, J.A., Badimon, L., Badimon, J.J., Chesebro, J.H. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990, 82: II47-59.
3. Bick, R.L., Kaplan, H. Syndromes of thrombosis and hypercoagulability. Congenital and acquired causes of thrombosis. Med Clin North Am 1998, 82: 409-58.
4. Fareed, J., Hoppensteadt, D., Bick, R.L. New antithrombotic drugs: A perspective. Curr Opin Cardiovasc Pulm Renal Invest Drugs 1999, 1: 40-55.
5. Turpie, A.G. Clinical potential of antithrombotic drugs in coronary syndromes. Am J Cardiol 1998, 82: 11-4L.
6. Triplett, D.A. Current recommendations for warfarin therapy. Use and monitoring. Med Clin North Am 1998, 82: 601-11.
7. Douglas, S.A., Feuerstein, G.Z. Development of pharmacological adjuncts to coronary angioplasty for the prevention of restenosis. Curr Res Vasc Dis 1998, 3: 39-58.
8. Kieffer, N., Phillips, D.R. Platelet membrane glycoproteins: Functions in cellular interactions. Annu Rev Cell Biol 1990, 6: 329-57.
9. Weitz, J.I., Hirsh, J. New antithrombotic agents. Chest 1998, 114: 715-27S.
10. Prandoni, P., Lensing, A., Buller, H. et al. Comparison of subcutaneous standard low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992, 339: 441-5.
11. Hirsh, J., Levine, M. The development of low molecular weight heparins for clinical use. In: Thrombosis and Haemostasis. Verstraete, M. et al. (Eds.). Leuven University Press: Leuven 1987, 425-48.
12. Esmon, C.T. Cell mediated events that control blood coagulation and vascular injury. Ann Rev Cell Biol 1993, 9: 1-26.
13. Subbarao, V., Phillips, J., Stouffer, G.A. Update on glycoprotein IIb/IIIa inhibitors. Curr Opin Cardiovasc Pulm Renal Invest Drugs 1999, 1: 56-62.
14. Rewinkel, J.B.M., Adang, A.E.P. Strategies and progress towards the ideal orally active thrombin inhibitor. Curr Pharm Des 1999, 5: 1043-75.
15. Murayama, N., Tanaka, S., Kikuchi, T., Nakaoka, M., Sudo, K. Radioimmunoassay method for DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma. J Pharm Biomed Anal 1996, 14: 1435-45.
16. Topol, E.J., Byzova, T.V., Plow, E.F. Platelet GPIIb-IIIa blockers. Lancet 1999, 353: 227-31.
17. Kaiser, B. Thrombin and factor Xa inhibitors. Drugs Fut 1998, 23: 423-36.
18. Wiley, M., Fisher, M.J. Small-molecule direct thrombin inhibitors. Exp Opin Ther Pat 1997, 7: 1265-82.
19. Walenga, J.M., Jeske, W.P., Hoppensteadt, D., Kaiser, B. Factor Xa inhibitors: Today and beyond. Curr Opin Cardiovasc Pulm Renal Invest Drugs 1999, 1: 13-27.
20. Ruoslahti, E. RGD and other recognition sequences for integrins. Ann Rev Cell Dev Biol 1996, 12: 697-715.
21. 2-terminal fragments of the ("A") chain. J Biol Chem 1972, 247: 1496-512.
22. Butrowski, R.J., Elion, J., Downing, M.R., Mann, K.G. Primary structure of human prethrombin 2 and α-thrombin. J Biol Chem 1977, 252: 4942-57.
23. Alig, L., Edenhofer, A., Hadváry, P. et al. Low molecular weight non-peptide fibrinogen receptor antagonists. J Med Chem 1992, 35: 4393-407.
24. Hijikata-Okunomiya, A., Okamoto, S. A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost 1992, 18: 135-49.
25. Hara, T., Yokoyama, A., Ishihara, H., Yokoyama, Y., Nagahara, T., Iwamoto, M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994, 71: 314-9.
26. Navia, M.A., Chaturvedi, P.R. Design principles for orally bioavailable drugs. DDT 1996, 1: 179-89.
27. Chan, O.H., Stewart, B.H. Physicochemical and drug-delivery considerations for oral drug unavailability. DDT 1996, 1: 461-73.
28. Pauletti, G.M., Gangwar, S., Siahaan, T.J., Aubé, J., Borchardt, R.T. Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv Drug Deliv Rev 1997, 27: 235-56.
29. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997, 23: 3-25.
30. Palm, K., Luthman, K., Ungell, A.L. et al. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictors. J Med Chem 1998, 41: 5382-92.
31. Kelder, J., Grootenhuis, P.D.J., Bayada, D.M., Delbressine, L.P.C., Ploemen, J.-P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999, 16: 1514-9.
32. Swaan, P.W., Tukker, J.J. Molecular determinants of recognition for the intestinal peptide carrier. J Pharm Sci 1997, 86: 596-602.
33. Sixma, J.J., de Groot, P.G. The ideal antithrombotic drug. Thromb Res 1992, 67: 305-11.
34. Goa, K.L., Noble, S. Eptifibatide. Drugs 1999, 57: 439-62.
35. Scarborough, R.M. Eptifibatide. Drugs Fut 1998, 23: 585-90.
36. Weller, T., Alig, L., Beresini, M. et al. Orally active fibrinogen antagonists. 2. Amidoximes as pro-drugs of amidines. J Med Chem 1996, 39: 3139-47.
37. Olson, R.E., Sielecki, T.M., Wityak, J. et al. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action. J Med Chem 1999, 42: 1178-92.
38. 3-binding kinetics to c7E3. J Cardiovasc Pharmacol 1998, 32: 736-44.
39. Sugihara, H., Fukushi, H., Miyawaki, T. et al. Novel non-peptide fibrinogen antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide. J Med Chem 1998, 41: 489-502.
40. Gustafsson, D., Antonsson, T., Bylund, R. et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998, 79: 110-8.
41. Eriksson, H., Eriksson, U.G., Frison, L. et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999, 81: 358-63.
42. McElroy, A. Proteinase inhibition as a drug discovery strategy: Tackling the challenges of absorption, clearance and selectivity. 15th Int Symp Med Chem (Sept 6-10, Edinburgh) 1998, I-4.
43. Reers, M., Koschinsky, R., Dickneite, G., Hoffmann, D., Czech, J., Strüber W. Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine. J Enzyme Inhib 1995, 9: 61-72.
44. Strüber W., Koschinsky, R., Kolar et al. Inhibition of thrombin by derivatives of the dipeptide aspartic acid-amidinophenylalanine. Pept Chem Struct Biol 1994, 13: 643-5.
45. Prada, D., Svendsen, L., Sturzebecher, J. Inhibition of thrombin generation in plasma by inhibitors of factor Xa. Thromb Haemost 1997, 78: 1215-9.
46. Yokoyama, T., Kelly, A.B., Marzec, U.M., Hanson, S.R., Kunitada, S., Harker, L.A. Antithrombotic effects of orally active synthetic antagonist of activated factor Xa in nonhuman primates. Circulation 1995, 92: 485-91.
47. Sato, K., Taniuchi, Y., Kawasaki, T. et al. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice. Jpn J Pharmacol 1998, 78: 191-7.
48. Taniuchi, Y., Sakai, Y., Hisamichi, N. et al. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost 1998, 79: 543-8.
49. Merlos, M., Leeson, P.A., Castaner, J. Orbofiban acetate. Drugs Fut 1998, 23: 1190-8.
50. Mousa, S.A. et al. Novelnonpeptideantiplateletglycoprotein IIa/IIIb receptor antagonist, DMP754: Receptor binding affinity and specificity. Coron Artery Dis 1996, 7: 767-74.
51. Mousa, S.A., Wityak, J. Orally active isoxazoline GPIIb/IIIa antagonists. Cardiovasc Drug Rev 1998, 16: 48-61.
52. Zablocki, J.A., Rico, J.G., Garland, R.B. et al. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fribinogen. (Aminobenzamidine)succinyl (ABAS) series of orally active fribinogen receptor antagonists. J Med Chem 1995, 38: 2378-94.
53. Searle drops development of gpIIb/IIIa receptor antagonists. DailyDrugNews.com (Daily Essentials) Jan 25, 1999.
54. Spurlino, J.C., Lu, T., Illig, C., Soll, R.M., Bone, R. Structural analysis of thrombin inhibitors utilizing a phenyl-based peptide mimetic. 215th ACS Natl Meet (March 29-April 2, Dallas) 1998, Abst MEDI 198.
55. Novel thrombin inhibitor series from 3-D discussed at ACS meeting. DailyDrugNews.com (Daily Essentials) March 25, 1999.
56. Boatman, P.D., Ogbu, C.O., Eguchi, M. et al. Secondary structure peptide mimetics: Design, synthesis, and evaluation of β-strand thrombin inhibitors. J Med Chem 1999, 42: 1367-75.
57. Hauptmann, J., Sturzebecher, J. Synthetic inhibitors of thrombin and factor Xa: From bench to bedside. Thromb Res 1999, 93: 203-41.
58. Sturzebecher, J., Sturzebecher, U., Vieweg, H., Wagner, G., Hauptmann, J., Markwardt, F. Synthetic inhibitors of bovine factor Xa and thrombin. Comparison of their anticoagulant efficiency. Thromb Res 1989, 54: 245-52.
59. Quan, M.L., Ellis, C.D., Liauw, A.Y. et al. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. J Med Chem 1999, 42: 2760-73.
60. Ostrem, J.A., Al-Obeidi, F.A., Safar, P., et al. Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry. Biochemistry 1998, 37: 1053-9.
61. Cook, N.S., Bruttger, O., Pally, C., Hagenbach, A. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: Evidence that Ro 43-8857 is orally active. Thromb Haemost 1993, 70: 838-47.
62. Duggan, M.E., Naylor-Olsen, A.M., Perkins, J.J. et al. Non-peptide GPIIb/IIIa inhibitors. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. J Med Chem 1995, 38: 3332-41.
63. Egbertson, M.S., Cook, J.J., Bednar, B. et al. Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. J Med Chem 1999, 42: 2409-21.
64. Samanen, J.M., Ali, F.E., Barton, L.S. et al. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists. J Med Chem 1996, 39: 4867-70.
65. First volunteers dosed with R.W. Johnson's new gpIIb/IIIa antagonist. DailyDrugNews.com (Daily Essentials) Aug 14, 1998.
66. Hoekstra, W.J., Beavers, M.P., Andrade-Gordon, P. et al. Design and evaluation of nonpeptide fibrinogen γ-chain based GPIIb/IIIa antagonists. J Med Chem 1995, 38: 1582-92.
67. Adang, A.E.P., van Dinther, T.G., Visser, A. et al. A polar pharmacophore for oral bioavailability in thrombin inhibitors. EFMC 15th Int Symp Med Chem (Sept 6-10, Edinburgh) 1998, Abst P.157.
68. von der Saal, W. 4-Aminopyridine and related heterocycles as Pi residues in selective thrombin inhibitors. 9th RCS-SCI Med Chem Symp (Sept 7-10, Cambridge) 1997.
69. Engh, R.A., Brandstetter, H., Sucher, G. et al. Enzyme fexibility, solvent and "weak" interactions characterize thrombin-ligand interactions: Implications for drug design. Structure 1996, 4: 1353-62.
70. Weber, I.R., Neidlein, R., von der Saal, W. et al. Diarylsulfonamides as selective, non-peptidic thrombin inhibitors. Bioorg Med Chem Lett 1998, 8: 1613-8.
71. Tucker, T.J., Brady, S.F., Lumma, W.C. et al. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J Med Chem 1998, 41: 3210-9.
72. Sanderson, P.E.J., Lyle, E.A., Cutrona, K.J. et al. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates. J Med Chem 1998, 41: 4466-74.
73. Kim, I.-C., Oh, Y.S., Yun, M. et al. Discovery of a highly selective, orally bioavailable, direct thrombin inhibitor, LB30057. Circulation 1997, 96: 1-41.
74. Oh, Y.S., Yun, M., Hwang, S.Y. et al. Discovery of LB30057, a benzamidrazone-based selective, oral thrombin inhibitor. Bioorg Med Chem Lett 1998, 8: 631-4.
75. Rewinkel, J.B.M., Lucas, H., Smit, M.J. et al. Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett 1999, 9: 2837-42.
76. Ambler, J., Bentley, D., Brown, L. et al. The discovery of orally available thrombin inhibitors: Optimisation of the P1 pharmacophore. Bioorg Med Chem Lett 1999, 9: 1103-8.
77. Choi-Sledeski, Y.M., Becker, M.R., Green, D.M. et al. Aminoisoquinolines: Design and synthesis of an orally active benzamidine isostere for the inhibition of factor Xa. Bioorg Med Chem Lett 1999, 9: 2539-44.
78. Young, S.C., Brady, L., Jones, S.D. et al. Rational design of novel, potent and highly selective factor Xa inhibitors. 10th RSC-SCI Med Chem Symp (Sept 5-8, Cambridge) 1999.
79. Tucker, T.J., Lumma, W.C., Lewis, S.D. et al Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy. J Med Chem 1997, 40: 1565-9.
80. Kim, S., Hong, C.Y., Lee, E.J., Koh, J.S. Solid phase synthesis of benzylamine-derived sulfonamide library. Bioorg Med Chem Lett 1998, 8: 735-8.
81. Lee, K., Jung, W-H., Park, C.W. et al. Benzylamine-based selective and orally bioavailable inhibitors of thrombin. Bioorg Med Chem Lett 1998, 8: 2563-8.
82. Rewinkel, J.B.M., Lucas, H., van Galen, P.J.M. et al. 1-Aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors. Bioorg Med Chem Lett 1999, 9: 685-90.
83. van Boeckel C.A.A., van Galen, P.J.M., Rewinkel, J.B.M. Therapeutic compounds. WO 9847876.
84. AstraZeneca takes an ambitious approach to drug R&D. DailyDrugNews.com (Daily Essentials) Dec 13, 1999.
85. Müller, T.H., Weisenberger, H., Brickl, R. et al. Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active pro-drug, lefradafiban, in men. Circulation 1997, 96: 1130-8.
86. Guth, B.D., Seewaldt-Becker, E., Himmelsbach, F. et al. Antagonism of the GPIIb/IIIa receptor with the nonpetidic molecule B/BU52: Inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo. J Cardiovasc Pharmacol 1997, 30: 261-72.
87. Badorc, A., Bordes, M-F., de Cointet, P. et al. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: Indentification of ethyl 3-[N-[4-[4-[[amino[(ethyoxycarbonyl)imino]methyl]phenyl]-1,3-thiazl-2-yl]-N-[1- [(ethoxycarbonyl)methyl]-piperid-4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent. J Med Chem 1997, 40: 3393-401.
88. Antonsson, T., Gustafsson, D., Hoffmann, K., Nystrom, J., Sorensen, H., Sellen, M. Preparation of peptide derivatives as prodrugs of thrombin inhibitors. WO 9723499.
89. News flash: Highlights from the AstraZeneca pipeline review. DailyDrugNews.com (Daily Essentials) Dec 7, 1999.
90. Takeuchi, K., Kohn, T.J., Sail, D.J. et al. Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 4. SAR studies on the conformationally restricted C3-side chain of hydroxybenzo[b]thiophenes. Bioorg Med Chem Lett 1999, 9: 759-64.
91. Zhang, M., Bailey, D.L., Bastian, J.A. et al. Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 2. Side chain optimisation and demonstration of in vivo efficacy. Bioorg Med Chem Lett 1999, 9: 775-80.
92. Arnaiz, D.O., Chou, Y-L., Karanjawala, R.E. et al. Preparation of heteroarylcarbonylaminobenzamides and related compounds as anticoagulants. WO 9932477.
93. Beight, D.W., Craft, T.J., Franciskovich, J.B. et al. Preparation of bisamide pyridinediamines as antithrombotic agents. WO 9900126.